Chris Hollowood
Chairman at FREELINE THERAPEUTICS HOLDINGS PLC
Net worth: 1 M $ as of 2024-04-29
Network origin in Chris Hollowood first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
University of Cambridge
238
| College/University | Other Consumer Services | 238 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.
35
| Subsidiary | Investment Managers | 35 |
| Subsidiary | Biotechnology | 28 | |
| Subsidiary | Pharmaceuticals: Major | 20 | |
| Subsidiary | Pharmaceuticals: Generic | 19 | |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom.
14
| Subsidiary | Biotechnology | 14 |
| Private Company | Biotechnology | 14 | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA.
11
| Private Company | Biotechnology | 11 |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom.
9
| Private Company | Pharmaceuticals: Major | 9 |
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom.
5
| Subsidiary | Investment Managers | 5 |
Forcefield Therapeutics Ltd.
5
| Private Company | 5 | |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Swanbio Therapeutics Ltd.
 Swanbio Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Swanbio Therapeutics Ltd. engages in the research and experimental development of biotechnology. The company was founded on September 1, 2017 and is headquartered in London, the United Kingdom.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Chris Hollowood via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| University of Oxford | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal Chief Executive Officer Private Equity Investor Chief Executive Officer | |
| MACROGENICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder | |
| University College London | College/University | Undergraduate Degree Undergraduate Degree Corporate Officer/Principal | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member Founder Director/Board Member | |
Resolution Therapeutics Ltd.
 Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| Stanford University | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree | |
| JAZZ PHARMACEUTICALS PLC | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member President | |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| The University of Edinburgh | College/University | Undergraduate Degree Graduate Degree | |
Blue Earth Diagnostics Ltd.
 Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Chairman Director/Board Member | |
| University of Glasgow | College/University | Doctorate Degree Undergraduate Degree | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| Georgetown University | College/University | Undergraduate Degree Undergraduate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Private Equity Investor | |
| Imperial College London | College/University | Doctorate Degree Doctorate Degree | |
| NXERA PHARMA CO., LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Undergraduate Degree | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Pharmaceuticals: Generic | Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Private Equity Investor | |
Eyebiotech Ltd.
 Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | Pharmaceuticals: Major | Founder Private Equity Investor | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
| University of Aberdeen | College/University | Undergraduate Degree Undergraduate Degree | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Founder Director of Finance/CFO | |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member | |
| DECHRA PHARMACEUTICALS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Azeria Therapeutics Ltd.
 Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member | |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor Private Equity Investor | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Chairman Chief Executive Officer | |
Orbit Biomedical Ltd.
 Orbit Biomedical Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2018, Orbit Biomedical Ltd. is a British biotechnology company that engages in research and development. Part of Novartis AG, the company is based in Stevenage, UK. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Administrative Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
GRAIL LLC
 GRAIL LLC Electronic Equipment/InstrumentsElectronic Technology GRAIL LLC is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA. | Electronic Equipment/Instruments | Chief Executive Officer Director of Finance/CFO | |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| London School of Economics & Political Science | College/University | Graduate Degree Graduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Haas School of Business | College/University | Masters Business Admin Masters Business Admin | |
| Royal Academy of Engineering | College/University | Corporate Officer/Principal Chairman | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree Undergraduate Degree |
Statistics
International
| United States | 24 |
| United Kingdom | 23 |
| Denmark | 3 |
| Switzerland | 2 |
| Ireland | 2 |
Sectoral
| Health Technology | 27 |
| Consumer Services | 16 |
| Commercial Services | 5 |
| Health Services | 3 |
| Miscellaneous | 2 |
Operational
| Director/Board Member | 340 |
| Corporate Officer/Principal | 150 |
| Independent Dir/Board Member | 82 |
| Undergraduate Degree | 62 |
| Private Equity Investor | 49 |
Most connected contacts
| Insiders | |
|---|---|
| Simon Holden | 40 |
| Martin Murphy | 33 |
| Ken Galbraith | 30 |
| Roel Bulthuis | 29 |
| Edward Hurwitz | 27 |
| Alison Lawton | 24 |
| Anne VanLent | 23 |
| Julia Gregory | 22 |
| Bryan Geoffrey Morton | 22 |
| Susan B. Washer | 17 |
| David Fellows | 16 |
| James Rosen | 16 |
| Jeffrey Chodakewitz | 15 |
| Hitesh Thakrar | 14 |
| Anne Prener | 14 |
- Stock Market
- Insiders
- Chris Hollowood
- Company connections
